| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018231948 | 2018-12-11 | ||
| PCT/JP2019/048171WO2020122034A1 (en) | 2018-12-11 | 2019-12-10 | Combination of antibody-drug conjugate with parp inhibitor |
| Publication Number | Publication Date |
|---|---|
| EA202191641A1true EA202191641A1 (en) | 2021-09-13 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191641AEA202191641A1 (en) | 2018-12-11 | 2019-12-10 | ANTIBODY-DRUG CONJUGATE COMBINATION WITH PARP INHIBITOR |
| Country | Link |
|---|---|
| US (1) | US20220023436A1 (en) |
| EP (1) | EP3909580A4 (en) |
| JP (2) | JP7608164B2 (en) |
| KR (1) | KR20210102341A (en) |
| CN (1) | CN113271942A (en) |
| AU (1) | AU2019396895B2 (en) |
| BR (1) | BR112021011119A2 (en) |
| CA (1) | CA3122946A1 (en) |
| EA (1) | EA202191641A1 (en) |
| SG (1) | SG11202106248XA (en) |
| TW (1) | TW202034959A (en) |
| WO (1) | WO2020122034A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230270870A1 (en)* | 2019-05-29 | 2023-08-31 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate |
| KR20230084163A (en)* | 2020-10-09 | 2023-06-12 | 아스트라제네카 유케이 리미티드 | Combination of Antibody-Drug Conjugates with PARP1 Selective Inhibitors |
| WO2022248268A1 (en)* | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US20250025568A1 (en) | 2021-11-18 | 2025-01-23 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| US20250114471A1 (en)* | 2022-04-12 | 2025-04-10 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| AU2023274540A1 (en)* | 2022-05-24 | 2024-12-12 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
| TW202444423A (en)* | 2023-03-14 | 2024-11-16 | 日商第一三共股份有限公司 | Combination of anti-cdh6 antibody-drug conjugate and vegf inhibitor |
| WO2024204679A1 (en)* | 2023-03-31 | 2024-10-03 | 第一三共株式会社 | Combination of anti-cdh6 antibody-drug conjugate and hif-2a inhibitor |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| EP4495003A1 (en) | 2023-07-20 | 2025-01-22 | AIRBUS HELICOPTERS DEUTSCHLAND GmbH | An external cargo adapter for use with a rotorcraft |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP3031917A1 (en) | 1999-04-09 | 2016-06-15 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| BRPI0012198B8 (en) | 1999-06-25 | 2021-05-25 | Genentech Inc | humanized antibodies, composition and immunoconjugate |
| EA013563B1 (en) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies |
| AR056857A1 (en) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
| EP2001358B1 (en) | 2006-03-27 | 2016-07-13 | University Of Maryland, Baltimore | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| HRP20131113T1 (en) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| BR112014019825B1 (en) | 2012-02-10 | 2021-08-24 | University Of Maryland, Baltimore | CHEMIOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS OF THE SAME |
| BR122021014396B1 (en) | 2012-10-11 | 2022-07-05 | Daiichi Sankyo Company, Limited | INTERMEDIATE DRUG BINDING COMPOUNDS, AND BINDING |
| ES2782248T3 (en) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure |
| KR102535900B1 (en) | 2013-12-25 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | Anti-trop2 antibody-drug conjugate |
| PH12020552271A1 (en)* | 2014-01-31 | 2022-05-02 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (en) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | Anti-CD98 antibody-drug conjugate |
| JP6105171B2 (en) | 2014-04-10 | 2017-03-29 | 第一三共株式会社 | Anti-HER3 antibody-drug conjugate |
| WO2015155976A1 (en) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | (anti-her2 antibody)-drug conjugate |
| US10195175B2 (en)* | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| EP3315512B1 (en) | 2015-06-29 | 2022-11-23 | Daiichi Sankyo Co., Ltd. | Method for selectively manufacturing antibody-drug conjugate |
| TWI780104B (en) | 2017-01-17 | 2022-10-11 | 日商第一三共股份有限公司 | Anti gpr20 antibodies and anti gpr20 antibody-drug conjugates, as well as manufacturing method and use thereof |
| TW202504644A (en) | 2017-05-15 | 2025-02-01 | 日商第一三共股份有限公司 | Use of antibody-drug conjugates |
| BR112020003646A2 (en) | 2017-08-31 | 2020-09-01 | Daiichi Sankyo Company, Limited | crystals, methods for producing crystals and an antibody-drug conjugate, and, salt. |
| Publication number | Publication date |
|---|---|
| SG11202106248XA (en) | 2021-07-29 |
| EP3909580A1 (en) | 2021-11-17 |
| KR20210102341A (en) | 2021-08-19 |
| TW202034959A (en) | 2020-10-01 |
| JPWO2020122034A1 (en) | 2021-10-28 |
| AU2019396895A1 (en) | 2021-07-08 |
| JP2025041725A (en) | 2025-03-26 |
| US20220023436A1 (en) | 2022-01-27 |
| CA3122946A1 (en) | 2020-06-18 |
| AU2019396895B2 (en) | 2025-09-11 |
| WO2020122034A1 (en) | 2020-06-18 |
| EP3909580A4 (en) | 2022-09-07 |
| JP7608164B2 (en) | 2025-01-06 |
| CN113271942A (en) | 2021-08-17 |
| BR112021011119A2 (en) | 2022-01-25 |
| Publication | Publication Date | Title |
|---|---|---|
| EA202191641A1 (en) | ANTIBODY-DRUG CONJUGATE COMBINATION WITH PARP INHIBITOR | |
| EA202190471A1 (en) | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR | |
| MX2020012997A (en) | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE. | |
| EA202192137A1 (en) | AMATOXY ANALOGUE CONJUGATE WITH BRANCHED LINKERS | |
| EA202190403A1 (en) | TREATMENT OF METASTATIC BRAIN TUMOR BY INJECTING AN ANTIBODY-DRUG CONJUGATE | |
| CY1121949T1 (en) | PHARMACEUTICAL FORMS OF ANTI-EGFR ANTIBODY-DRUG CONJUGATE | |
| WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
| BR112016017893A2 (en) | anti-her3 antibody-drug conjugate | |
| CL2024000282A1 (en) | Herboxydiene antibody-drug conjugates and methods of use (divisional). | |
| BR112023006337A2 (en) | PHARMACEUTICAL PRODUCT, USE OF AN ANTI-HER2-DRUG ANTIBODY CONJUGATE OR A SELECTIVE PARP1 INHIBITOR, AND, METHOD OF TREATMENT OF CANCER | |
| EA202191175A1 (en) | CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS | |
| CO2024006160A2 (en) | Camptothecin bispecific antibody-drug conjugate and its pharmaceutical use | |
| AR117652A1 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING CONJUGATES OF ANTI-191P4D12 ANTIBODY AND DRUG AND METHODS OF USING THEM | |
| BR112023008845A2 (en) | PHARMACEUTICAL COMPOSITION, AND TREATMENT METHOD | |
| CU20210047A7 (en) | ANTI-PMEL 17 ANTIBODIES AND CONJUGATES THEREOF | |
| SG11201903084UA (en) | Cysteine modified antibody-drug conjugate and preparation method thereof | |
| CL2023000099A1 (en) | Inflammatory disease treatment using anti-tissue factor antibodies | |
| UY38265A (en) | DRUG ANTIBODY CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS | |
| MX2023001238A (en) | ANTIGEN BINDING PROTEIN. | |
| EA202092951A1 (en) | ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION | |
| AR123512A1 (en) | THERAPEUTIC CONJUGATES | |
| WO2019089594A8 (en) | Combination treatment with antibody-drug conjugates and cytarabine | |
| EA202092902A1 (en) | TREATMENT OF HER2-MUTATED CANCER WITH ANTI-HER2-ANTI-BODY-DRUG CONJUGATE | |
| AR124059A2 (en) | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | |
| AR117686A1 (en) | HERBOXIDIENE SPLIT MODULATOR OF ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |